Does the media prefer INO or MRNA?

In the previous week, Moderna had 46 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 47 mentions for Moderna and 1 mentions for Inovio Pharmaceuticals. Moderna's average media sentiment score of 0.47 beat Inovio Pharmaceuticals' score of 0.00 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 22 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 11 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ELMD or INO?

In the previous week, Electromed and Electromed both had 1 articles in the media. Electromed's average media sentiment score of 1.91 beat Inovio Pharmaceuticals' score of 0.00 indicating that Electromed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Electromed 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Inovio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CARL or INO?

In the previous week, Carlsmed and Carlsmed both had 1 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 0.00 beat Carlsmed's score of -0.35 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carlsmed 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Inovio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer INO or SI?

In the previous week, Shoulder Innovations had 2 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 3 mentions for Shoulder Innovations and 1 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.00 beat Shoulder Innovations' score of -0.71 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Shoulder Innovations 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Inovio Pharmaceuticals (INO) Competitors

$1.12 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$1.12 +0.01 (+0.72%)

As of 06/18/2026 07:56 PM Eastern

Compare

INO vs. MRNA, CV, ELMD, CARL, and SI

Should you buy Inovio Pharmaceuticals stock or one of its competitors? MarketBeat compares Inovio Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inovio Pharmaceuticals include Moderna (MRNA), CapsoVision (CV), Electromed (ELMD), Carlsmed (CARL), and Shoulder Innovations (SI).

How does Inovio Pharmaceuticals compare to Moderna?

Inovio Pharmaceuticals (NASDAQ:INO) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%
Moderna	-143.55%	-26.64%	-19.32%

Inovio Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Inovio Pharmaceuticals has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,528.85	-$84.95M	-$1.45	N/A
Moderna	$1.94B	13.05	-$2.82B	-$8.15	N/A

Inovio Pharmaceuticals currently has a consensus price target of $4.25, suggesting a potential upside of 281.17%. Moderna has a consensus price target of $36.60, suggesting a potential downside of 42.78%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Moderna had 46 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 47 mentions for Moderna and 1 mentions for Inovio Pharmaceuticals. Moderna's average media sentiment score of 0.47 beat Inovio Pharmaceuticals' score of 0.00 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	22 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	11 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Inovio Pharmaceuticals beats Moderna on 9 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to CapsoVision?

Inovio Pharmaceuticals (NASDAQ:INO) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Inovio Pharmaceuticals has a net margin of 0.00% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%
CapsoVision	-198.87%	N/A	-136.03%

Inovio Pharmaceuticals currently has a consensus target price of $4.25, suggesting a potential upside of 281.17%. CapsoVision has a consensus target price of $8.50, suggesting a potential upside of 28.59%. Given Inovio Pharmaceuticals' higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 2.3% of CapsoVision shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CapsoVision has higher revenue and earnings than Inovio Pharmaceuticals. CapsoVision is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,528.85	-$84.95M	-$1.45	N/A
CapsoVision	$13.55M	24.37	-$25.32M	-$2.34	N/A

In the previous week, Inovio Pharmaceuticals had 1 more articles in the media than CapsoVision. MarketBeat recorded 1 mentions for Inovio Pharmaceuticals and 0 mentions for CapsoVision. CapsoVision's average media sentiment score of 0.76 beat Inovio Pharmaceuticals' score of 0.00 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Overall Sentiment
Inovio Pharmaceuticals	Neutral
CapsoVision	Positive

Summary

Inovio Pharmaceuticals beats CapsoVision on 9 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Electromed?

Electromed (NYSE:ELMD) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

Electromed currently has a consensus price target of $37.50, indicating a potential downside of 3.05%. Inovio Pharmaceuticals has a consensus price target of $4.25, indicating a potential upside of 281.17%. Given Inovio Pharmaceuticals' higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Electromed has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

In the previous week, Electromed and Electromed both had 1 articles in the media. Electromed's average media sentiment score of 1.91 beat Inovio Pharmaceuticals' score of 0.00 indicating that Electromed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Electromed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Inovio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Electromed has a net margin of 11.34% compared to Inovio Pharmaceuticals' net margin of 0.00%. Electromed's return on equity of 15.71% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

40.8% of Electromed shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 10.5% of Electromed shares are owned by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Electromed has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	4.46	$5.15M	$1.17	33.06
Inovio Pharmaceuticals	$60K	1,528.85	-$84.95M	-$1.45	N/A

Summary

Electromed beats Inovio Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Carlsmed?

Carlsmed (NASDAQ:CARL) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Carlsmed and Carlsmed both had 1 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 0.00 beat Carlsmed's score of -0.35 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Carlsmed	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inovio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inovio Pharmaceuticals has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

Carlsmed currently has a consensus target price of $19.33, indicating a potential upside of 93.33%. Inovio Pharmaceuticals has a consensus target price of $4.25, indicating a potential upside of 281.17%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Carlsmed has higher revenue and earnings than Inovio Pharmaceuticals. Carlsmed is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	5.38	-$29.63M	-$2.51	N/A
Inovio Pharmaceuticals	$60K	1,528.85	-$84.95M	-$1.45	N/A

Summary

Inovio Pharmaceuticals beats Carlsmed on 10 of the 14 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Shoulder Innovations?

Inovio Pharmaceuticals (NASDAQ:INO) and Shoulder Innovations (NYSE:SI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Shoulder Innovations had 2 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 3 mentions for Shoulder Innovations and 1 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.00 beat Shoulder Innovations' score of -0.71 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Shoulder Innovations	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Inovio Pharmaceuticals has a net margin of 0.00% compared to Shoulder Innovations' net margin of -81.78%. Shoulder Innovations' return on equity of -35.11% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%
Shoulder Innovations	-81.78%	-35.11%	-20.58%

Inovio Pharmaceuticals presently has a consensus price target of $4.25, suggesting a potential upside of 281.17%. Shoulder Innovations has a consensus price target of $21.00, suggesting a potential upside of 12.66%. Given Inovio Pharmaceuticals' higher possible upside, equities research analysts clearly believe Inovio Pharmaceuticals is more favorable than Shoulder Innovations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Shoulder Innovations	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by insiders. Comparatively, 29.0% of Shoulder Innovations shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Shoulder Innovations has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Shoulder Innovations, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,528.85	-$84.95M	-$1.45	N/A
Shoulder Innovations	$47.32M	8.17	-$40.36M	-$166.96	N/A

Summary

Shoulder Innovations beats Inovio Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Inovio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INO vs. The Competition

Export

Metric	Inovio Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$91.74M	$3.39B	$6.42B	$12.60B
Dividend Yield	N/A	2.32%	2.68%	5.67%
P/E Ratio	-0.77	19.56	24.73	24.42
Price / Sales	1,528.85	319.38	528.42	112.33
Price / Cash	N/A	127.84	45.07	55.09
Price / Book	3.10	8.16	10.83	6.58
Net Income	-$84.95M	$23.89M	$3.57B	$337.17M
7 Day Performance	1.36%	2.52%	0.71%	0.61%
1 Month Performance	-8.61%	5.96%	3.97%	5.02%
1 Year Performance	-42.82%	53.47%	28.54%	35.52%

Inovio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INO Inovio Pharmaceuticals	1.6306 of 5 stars	$1.12 flat	$4.25 +281.2%	-42.8%	$91.74M	$60K	N/A	320	Analyst Upgrade
MRNA Moderna	1.234 of 5 stars	$47.80 +0.8%	$35.73 -25.2%	+151.8%	$18.94B	$2.20B	N/A	4,700	Trending News Analyst Forecast Insider Trade Options Volume
CV CapsoVision	1.7845 of 5 stars	$6.96 -3.2%	$8.50 +22.1%	N/A	$349.80M	$13.56M	N/A	90
ELMD Electromed	1.3445 of 5 stars	$38.25 +1.5%	$37.50 -1.9%	+86.5%	$316.66M	$71.75M	50.99	160	Positive News
CARL Carlsmed	3.1615 of 5 stars	$11.54 +4.3%	$19.33 +67.5%	N/A	$307.68M	$50.51M	N/A	100	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INO) was last updated on 6/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, CV, ELMD, CARL, and SI

How does Inovio Pharmaceuticals compare to Moderna?

Summary

How does Inovio Pharmaceuticals compare to CapsoVision?

Summary

How does Inovio Pharmaceuticals compare to Electromed?

Summary

How does Inovio Pharmaceuticals compare to Carlsmed?

Summary

How does Inovio Pharmaceuticals compare to Shoulder Innovations?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, CV, ELMD, CARL, and SI

How does Inovio Pharmaceuticals compare to Moderna?

Is INO or MRNA more profitable?

Which has more risk and volatility, INO or MRNA?

Which has preferable valuation and earnings, INO or MRNA?

Do analysts recommend INO or MRNA?

Do insiders and institutionals hold more shares of INO or MRNA?

Does the media prefer INO or MRNA?

Summary

How does Inovio Pharmaceuticals compare to CapsoVision?

Is INO or CV more profitable?

Do analysts prefer INO or CV?

Do insiders & institutionals hold more shares of INO or CV?

Which has stronger earnings and valuation, INO or CV?

Does the media favor INO or CV?

Summary

How does Inovio Pharmaceuticals compare to Electromed?

Do analysts prefer ELMD or INO?

Which has more risk and volatility, ELMD or INO?

Does the media favor ELMD or INO?

Is ELMD or INO more profitable?

Do institutionals and insiders believe in ELMD or INO?

Which has higher valuation and earnings, ELMD or INO?

Summary

How does Inovio Pharmaceuticals compare to Carlsmed?

Do insiders and institutionals believe in CARL or INO?

Does the media favor CARL or INO?

Is CARL or INO more profitable?

Do analysts rate CARL or INO?

Which has preferable valuation & earnings, CARL or INO?

Summary

How does Inovio Pharmaceuticals compare to Shoulder Innovations?

Does the media prefer INO or SI?

Is INO or SI more profitable?

Do analysts rate INO or SI?

Do insiders & institutionals hold more shares of INO or SI?

Which has preferable valuation & earnings, INO or SI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools